Copyright
©The Author(s) 2021.
World J Nephrol. Nov 25, 2021; 10(6): 109-121
Published online Nov 25, 2021. doi: 10.5527/wjn.v10.i6.109
Published online Nov 25, 2021. doi: 10.5527/wjn.v10.i6.109
Table 3 Frequency of patients with factors potentially affecting erythropoiesis-stimulating agent response (n = 30)
| Factors potentially affecting ESA response | n (%) |
| Thalassemia | 1 (3.33) |
| Infection | 11 (36.67) |
| Hemolysis | 0 |
| Blood loss | 0 |
| Hyperparathyroidism | 1 (3.33) |
| Low blood folic acid | 0 |
| Iron deficiency | 3 (10.00) |
- Citation: Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121
- URL: https://www.wjgnet.com/2220-6124/full/v10/i6/109.htm
- DOI: https://dx.doi.org/10.5527/wjn.v10.i6.109